BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu KQ, Kyulo NL, Esrailian E, Thompson K, Chase R, Hillebrand DJ, Runyon BA. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol. 2004;40:147-154. [PMID: 14672626 DOI: 10.1016/s0168-8278(03)00479-3] [Cited by in Crossref: 84] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Mackawy AM, Badawi ME, Megahed O. Patatin-like phospholipase domain containing-3 gene (PNPLA3) I148M polymorphism and liver damage in chronic hepatitis C Egyptian patients. Egyptian Journal of Medical Human Genetics 2015;16:333-41. [DOI: 10.1016/j.ejmhg.2015.06.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Hu KQ, Currie SL, Shen H, Cheung RC, Ho SB, Bini EJ, McCracken JD, Morgan T, Bräu N, Schmidt WN. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Dig Dis Sci. 2007;52:570-578. [PMID: 17226072 DOI: 10.1007/s10620-006-9418-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
3 Minato T, Tsutsumi M, Tsuchishima M, Hayashi N, Saito T, Matsue Y, Toshikuni N, Arisawa T, George J. Binge alcohol consumption aggravates oxidative stress and promotes pathogenesis of NASH from obesity-induced simple steatosis. Mol Med. 2014;20:490-502. [PMID: 25180626 DOI: 10.2119/molmed.2014.00048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
4 Dyal HK, Aguilar M, Bhuket T, Liu B, Holt EW, Torres S, Cheung R, Wong RJ. Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review. Dig Dis Sci 2015;60:2813-24. [DOI: 10.1007/s10620-015-3760-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
5 Lin MS, Lin HS, Chung CM, Lin YS, Chen MY, Chen PH, Hu JH, Chou WN, Huang JC, Huang TJ. Serum aminotransferase ratio is independently correlated with hepatosteatosis in patients with HCV: a cross-sectional observational study. BMJ Open 2015;5:e008797. [PMID: 26369802 DOI: 10.1136/bmjopen-2015-008797] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
6 Mera K, Uto H, Mawatari S, Ido A, Yoshimine Y, Nosaki T, Oda K, Tabu K, Kumagai K, Tamai T, Moriuchi A, Oketani M, Shimada Y, Hidaka M, Eguchi S, Tsubouchi H. Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C. BMC Gastroenterol 2014;14:27. [PMID: 24524410 DOI: 10.1186/1471-230X-14-27] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
7 El Kassas M, Alboraie M, Naguib M, Omar H, Tahan AE, Moaz I, Abdellah M, Ezzat S, Wifi MN, Sherief AF, Eltabbakh M, Abdelsalam L, Eissa AH, Omran D. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. Turk J Gastroenterol 2019;30:708-13. [PMID: 31418415 DOI: 10.5152/tjg.2019.18514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL; HALT-C Trial Group. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010;138:136-46. [PMID: 19766643 DOI: 10.1053/j.gastro.2009.09.007] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
9 Estefan S, Brandão-Melo CE, Dos Santos Silva CM, Gomes DCK, Cardoso P, Costa MHS. Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents. Front Med (Lausanne) 2021;8:631600. [PMID: 34136497 DOI: 10.3389/fmed.2021.631600] [Reference Citation Analysis]
10 Price JC, Ma Y, Scherzer R, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC. Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection. Hepatology 2017;65:853-63. [PMID: 27981599 DOI: 10.1002/hep.28968] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
11 Treeprasertsuk S, Komolmit P, Tanyaowalak W. Adipokines, insulin resistance, hepatic steatosis, and necroinflammation in patients with chronic viral hepatitis. Asian Biomedicine 2014;8:557-64. [DOI: 10.5372/1905-7415.0804.327] [Reference Citation Analysis]
12 Nakamura M, Kanda T, Nakamoto S, Miyamura T, Jiang X, Wu S, Yokosuka O. No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV. PLoS One. 2013;8:e81312. [PMID: 24349054 DOI: 10.1371/journal.pone.0081312.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, Nascimbeni F, Loria P. Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen. World J Gastroenterol 2014; 20(23): 7089-7103 [PMID: 24966582 DOI: 10.3748/wjg.v20.i23.7089] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
14 Shire NJ, Yin M, Chen J, Railkar RA, Fox-Bosetti S, Johnson SM, Beals CR, Dardzinski BJ, Sanderson SO, Talwalkar JA, Ehman RL. Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C. J Magn Reson Imaging. 2011;34:947-955. [PMID: 21751289 DOI: 10.1002/jmri.22716] [Cited by in Crossref: 98] [Cited by in F6Publishing: 86] [Article Influence: 8.9] [Reference Citation Analysis]
15 Runyon BA. A Primer on Detecting Cirrhosis and Caring for These Patients without Causing Harm. Int J Hepatol. 2011;2011:801983. [PMID: 22121492 DOI: 10.4061/2011/801983] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
16 Martinez V, Ta TD, Mokhtari Z, Guiguet M, Miailhes P, Valantin MA, Charlotte F, Bertheau P, Molina JM, Katlama C, Caumes E. Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals. BMC Res Notes 2012;5:180. [PMID: 22490728 DOI: 10.1186/1756-0500-5-180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Clark PJ, Thompson AJ, Zhu Q, Vock DM, Zhu M, Patel K, Harrison SA, Naggie S, Ge D, Tillmann HL. The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci. 2012;57:2213-2221. [PMID: 22543885 DOI: 10.1007/s10620-012-2171-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
18 Nakamura M, Kanda T, Nakamoto S, Miyamura T, Jiang X, Wu S, Yokosuka O. No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV. PLoS One. 2013;8:e81312. [PMID: 24349054 DOI: 10.1371/journal.pone.0081312] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
19 Solis-Herruzo JA, Pérez-Carreras M, Rivas E, Fernández-Vázquez I, Garfia C, Bernardos E, Castellano G, Colina F. Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C. Am J Gastroenterol 2005;100:1091-8. [PMID: 15842583 DOI: 10.1111/j.1572-0241.2005.41059.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
20 Rocha R, Cotrim HP, Carvalho FM, Siqueira AC, Braga H, Freitas LA. Body mass index and waist circumference in non-alcoholic fatty liver disease. J Hum Nutr Diet 2005;18:365-70. [PMID: 16150132 DOI: 10.1111/j.1365-277X.2005.00634.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
21 Kemmer N, Neff GW. Managing chronic hepatitis C in the difficult-to-treat patient. Liver Int. 2007;27:1297-1310. [PMID: 18036096 DOI: 10.1111/j.1478-3231.2007.01613.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
22 Rawlins SR, El-Zammar O, Zinkievich JM, Newman N, Levine RA. Digital quantification is more precise than traditional semiquantitation of hepatic steatosis: correlation with fibrosis in 220 treatment-naïve patients with chronic hepatitis C. Dig Dis Sci 2010;55:2049-57. [PMID: 20458626 DOI: 10.1007/s10620-010-1254-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
23 Kanwal S, Mahmood T. Hepatitis C virus resistance to interferon therapy: an alarming situation. Open Life Sciences 2014;9:1155-67. [DOI: 10.2478/s11535-014-0352-8] [Reference Citation Analysis]
24 Hu KQ, Lee SM, Hu SX, Xia VW, Hillebrand DJ, Kyulo NL. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. Am J Gastroenterol 2005;100:2010-8. [PMID: 16128946 DOI: 10.1111/j.1572-0241.2005.51938.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
25 Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87:1-16. [PMID: 16436109 DOI: 10.1111/j.0959-9673.2006.00465.x] [Cited by in Crossref: 487] [Cited by in F6Publishing: 482] [Article Influence: 30.4] [Reference Citation Analysis]
26 Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG; HALT-C Trial Group. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009;137:549-557. [PMID: 19445938 DOI: 10.1053/j.gastro.2009.05.007] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 7.1] [Reference Citation Analysis]
27 Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006;43:1303-10. [PMID: 16729298 DOI: 10.1002/hep.21176] [Cited by in Crossref: 416] [Cited by in F6Publishing: 360] [Article Influence: 26.0] [Reference Citation Analysis]
28 Balzan S, Nagarajan G, Farges O, Galleano CZ, Dokmak S, Paugam C, Belghiti J. Safety of Liver Resections in Obese and Overweight Patients. World J Surg 2010;34:2960-8. [DOI: 10.1007/s00268-010-0756-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
29 Hu KQ. Hepatitis B virus (HBV) infection in Asian and Pacific Islander Americans (APIAs): how can we do better for this special population? Am J Gastroenterol 2008;103:1824-33. [PMID: 18479498 DOI: 10.1111/j.1572-0241.2008.01878.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
30 Livingston SE, Deubner H, Bruden DL, McMahon BJ, Homan CE, Townshend-Bulson LJ, Bruce MG, Hennessy TW, Williams JL, Gretch DR. Factors associated with the progression of fibrosis on liver biopsy in Alaska Native and American Indian persons with chronic hepatitis C. Can J Gastroenterol 2010;24:445-51. [PMID: 20652161 DOI: 10.1155/2010/692036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
31 Harrison SA. HCV therapy in 2006: down with ALT levels, in with awareness of co-existent metabolic syndrome. J Hepatol 2006;44:624-6. [PMID: 16503073 DOI: 10.1016/j.jhep.2006.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Delgado-Borrego A, Healey D, Negre B, Christofi M, Sabharwal S, Ludwig DA, Chung RT, Jonas MM. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2010;51:191-7. [PMID: 20531022 DOI: 10.1097/MPG.0b013e3181d32756] [Cited by in Crossref: 29] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
33 Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, Torbenson MS, Moore RD, Sulkowski MS. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology. 2011;140:809-817. [PMID: 21134375 DOI: 10.1053/j.gastro.2010.11.052] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
34 Hu KQ, Yang H, Lin YC, Lindsay KL, Redeker AG. Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States. Int J Med Sci 2004;1:92-100. [PMID: 15912201 DOI: 10.7150/ijms.1.92] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
35 Kawakubo M, Eguchi Y, Okada M, Iwane S, Oeda S, Otsuka T, Nakashita S, Araki N, Koga A. Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life. Intern Med 2018;57:1959-66. [PMID: 29526929 DOI: 10.2169/internalmedicine.0091-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
36 McKay A, Wilman HR, Dennis A, Kelly M, Gyngell ML, Neubauer S, Bell JD, Banerjee R, Thomas EL. Measurement of liver iron by magnetic resonance imaging in the UK Biobank population. PLoS One 2018;13:e0209340. [PMID: 30576354 DOI: 10.1371/journal.pone.0209340] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
37 Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004;99:860-5. [PMID: 15128351 DOI: 10.1111/j.1572-0241.2004.04152.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 6.5] [Reference Citation Analysis]
38 Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006;43:1177-86. [PMID: 16729327 DOI: 10.1002/hep.21239] [Cited by in Crossref: 101] [Cited by in F6Publishing: 76] [Article Influence: 6.3] [Reference Citation Analysis]
39 Lo Re V 3rd, Kostman JR. Management of chronic hepatitis C. Postgrad Med J 2005;81:376-82. [PMID: 15937203 DOI: 10.1136/pgmj.2004.025403] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
40 Takahama Y, Uto H, Kanmura S, Oketani M, Ido A, Kusumoto K, Hasuike S, Nagata K, Hayashi K, Stuver S, Okayama A, Tsubouchi H. Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan. J Gastroenterol 2008;43:942-50. [PMID: 19107338 DOI: 10.1007/s00535-008-2256-8] [Reference Citation Analysis]
41 Lonardo A, Loria P, Carulli N. Dysmetabolic changes associated with HCV: a distinct syndrome? Intern Emerg Med. 2008;3:99-108. [PMID: 18274709 DOI: 10.1007/s11739-008-0127-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]